[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100095205":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":13,"centralContacts":17,"locations":27,"responsibleParty":44,"collaborators":7,"id":46,"slug":7,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":52,"sex":53,"minAge":7,"maxAge":7,"enrollmentInfo":54,"targetDuration":57,"studyType":58,"phases":7,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":29,"whyStopped":7,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},{"fullName":5,"class":6},"University of Florida","OTHER",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"PROCEDURE","Alpha-1 Antitrypsin Genotype","Home fingerstick testing for alpha-1 antitrypsin genotype",[14],{"name":15,"affiliation":5,"role":16},"Karina Serban, M.D.","PRINCIPAL_INVESTIGATOR",[18,23],{"name":19,"role":20,"phone":21,"phoneExt":7,"email":22},"Michelle Owens, RN, BSN","CONTACT","352-273-6339","Sandra.Owens@medicine.ufl.edu",{"name":24,"role":20,"phone":25,"phoneExt":7,"email":26},"Allison Faunce, B.A.","352-273-8666","Allison.Faunce@medicine.ufl.edu",[28],{"facility":5,"status":29,"city":30,"state":31,"zip":32,"country":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"RECRUITING","Gainesville","Florida","32610","United States",{"type":35,"coordinates":36},"Point",[37,38],-82.32483,29.65163,{"lat":38,"lon":37},[41,42,43],{"name":19,"role":20,"phone":21,"phoneExt":7,"email":22},{"name":24,"role":20,"phone":25,"phoneExt":7,"email":26},{"name":15,"role":16,"phone":7,"phoneExt":7,"email":7},{"type":45,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100095205",false,"NCT00500123","The Alpha-1 Foundation's and University of Florida's Alpha-1 Coded Testing (ACT) Study","ACT","Inclusion Criteria:\n\n* Individuals of any age at risk for alpha-1 antitrypsin deficiency on the basis of symptoms or family genetic risk.\n\nExclusion Criteria:\n\n* Any person who has already had genotype and AAT level testing completed and has a qualified result.",true,"ALL",{"count":55,"type":56},50000,"ESTIMATED","50 Years","OBSERVATIONAL","The Alpha-1 Coded Testing (ACT) Study was established to study genetic testing and outcomes of individuals at risk for alpha-1 antitrypsin deficiency.",[61],"Alpha-1 Antitrypsin Deficiency",[63,64,65,66,67,68],"alpha-1","antitrypsin","AAT","genetic testing","alpha-1 antitrypsin deficiency","AATD","2025-11-21",{"date":71,"type":72},"2025-11-24","ACTUAL",{"date":74,"type":72},"2001-01",{"date":76,"type":56},"2050-01",{"name":5,"class":6},1]